Compounds | Metabolizing Enzymes | Human In Vivo Intrinsic Clearance | Relay Method Intrinsic Clearance ± S.E.a | Fold Difference between In Vitro and In Vivo |
---|---|---|---|---|
ml · min−1 · kg−1 | ml · min−1 · kg−1 | |||
Diazepam | CYP3A, CYP2C19 | 15 (Hallifax et al., 2010) | 15 ± 0.85 | 1.0 |
Disopyramide | CYP3A | 5.9 (Obach et al., 2008) | 4.8 ± 0.55 | 1.2 |
Theophylline | CYP1A2 | 2.6 (Hallifax et al., 2010) | 2.8 ± 0.60 | 1.1 |
Timolol | CYP2D6 | 36–49 (Obach et al., 2008; Hallifax et al., 2010) | 14 ± 2.5 | 2.6 |
Tolbutamide | CYP2C9 | 4.9 (Brown et al., 2007) | 7.4 ± 0.40 | 1.5 |
S-Warfarin | CYP3A, CYP2C9 | 4.5 (Hallifax et al., 2010) | 4.2 ± 0.65 | 1.1 |
Zolmitriptan | CYP1A2, MAO | 13 (Obach et al., 2008) | 3.5 ± 0.90b | 3.7b |